Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
February 28, 2018
Moberg Pharma Divests Balmex® for $4.25 Million
STOCKHOLM, Feb. 28, 2018 /PRNewswire/ --Moberg Pharma AB (OMX:MOB) has entered into an agreement with Randob Labs to divest the brand Balmex® for a total ...
February 28, 2018
BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Russell Skibsted, Chief ...
February 28, 2018
Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)
DURHAM, NC / ACCESSWIRE / February 28, 2018 / Heat Biologics, Inc. (HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system ...
February 28, 2018
Foamix Reports Fiscal Year 2017 Financial Results and Provides Corporate Update
REHOVOT, Israel, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on ...
February 28, 2018
Vermillion to Report Fourth Quarter and Fiscal Year 2017 Financial Results on Tuesday, March 13
AUSTIN, Texas, Feb. 28, 2018 (GLOBE NEWSWIRE) -- Vermillion, Inc. (VRML), a bio-analytical solutions company focused on gynecologic disease, announced today that it will report ...
February 28, 2018
AzurRx BioPharma to Present at the 30th Annual ROTH Conference (March 12th)
BROOKLYN, N.Y., Feb. 28, 2018 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant ...
February 28, 2018
Rockwell Medical Announces Triferic Presentations at the 2018 Annual Dialysis Conference
WIXOM, Mich., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), announced today that two Triferic abstracts have been selected for presentation at the ...
February 28, 2018
Genkyotex Announces 2017 Annual Financial Results
Genkyotex (GKTX.PA) (GKTX.PA) (Euronext Paris & Brussels: FR00011790542 – GKTX), a biopharmaceutical company and the leader in NOX therapies, announces its consolidated financial results for ...
February 28, 2018
OSE Immunotherapeutics Presenting at the Annual International Conference BIO-EUROPE SPRING®
NANTES, France, Feb. 28, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), announces it will be featured as a presenting company at the 12th Annual Conference BIO-EUROPE ...
February 28, 2018
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Corporate Update
SAN DIEGO, Feb. 28, 2018 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
February 27, 2018
HTG Announces New Australian Patent for Its Technology
TUCSON, Ariz., Feb. 26, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today ...
February 27, 2018
Arcturus Therapeutics Issues Statement Regarding Extraordinary General Meeting of Shareholders
SAN DIEGO, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (ARCT), a leading RNA medicines company, today announced that, based on the preliminary vote ...
February 27, 2018
Basilea reports significantly improved financial results in 2017
Basel, Switzerland, February 27, 2018 - Basilea Pharmaceutica Ltd. (SIX:BSLN) announced today its financial results for the financial year 2017 with total revenue increased to ...
February 27, 2018
OSE Immunotherapeutics Granted Approval to Resume Patient Accrual in U. S. for Phase 3 Tedopi® Clinical Trial in Advanced Non-Small Cell Lung Cancer Patients Following Immune Checkpoint Inhibitor Treatment
NANTES, France, Feb. 27, 2018 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics(ISIN:FR0012127173) (Mnémo:OSE), today announces that the first approvals to resume patient accrual in the global Tedopi® ...
February 27, 2018
Aimmune Therapeutics to Host Analyst and Investor Event Following Oral Late-Breaking Presentation of Phase 3 PALISADE Results on Sunday, March 4, at the AAAAI-WAO Joint Congress in Orlando
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Analyst and Investor ...
February 27, 2018
ADMA Biologics to Present at Raymond James’ 39th Annual Institutional Investors Conference
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 27, 2018 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
February 27, 2018
Sierra Oncology and Janssen Sign Supply Agreement for Prostate Cancer Study
VANCOUVER , Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response ...
February 27, 2018
Sierra Oncology Significantly Expands Clinical Development Program
VANCOUVER , Feb. 27, 2018 /CNW/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response ...
February 27, 2018
Sierra Oncology Reports 2017 Year End Results
VANCOUVER, Feb. 27, 2018 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response (DDR) ...
February 27, 2018
Zogenix to Release Fourth Quarter and Full-Year 2017 Financial Results and Host Conference Call and Webcast on March 6
EMERYVILLE, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
Page 95 of 150